Novo Nordisk A/S $NVO Shares Acquired by Markel Group Inc.

Markel Group Inc. increased its stake in Novo Nordisk A/S (NYSE:NVO) by 5.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,258,588 shares of the company’s stock after buying an additional 108,588 shares during the quarter. Novo Nordisk A/S comprises 1.3% of Markel Group Inc.’s portfolio, making the stock its 23rd largest position. Markel Group Inc.’s holdings in Novo Nordisk A/S were worth $155,888,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of NVO. North Capital Inc. acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $27,000. Stone House Investment Management LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $30,000. Disciplina Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares in the last quarter. Dagco Inc. purchased a new position in Novo Nordisk A/S in the first quarter valued at about $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $37,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Weiss Ratings restated a “hold (c)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, October 14th. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Rothschild Redb upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research note on Monday. They set an “underperform” rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $76.00.

Novo Nordisk A/S Stock Down 1.7%

Shares of Novo Nordisk A/S stock opened at $51.99 on Wednesday. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The business’s 50 day simple moving average is $56.49 and its 200-day simple moving average is $62.23. The stock has a market capitalization of $232.15 billion, a price-to-earnings ratio of 14.28, a PEG ratio of 2.40 and a beta of 0.68. Novo Nordisk A/S has a twelve month low of $45.05 and a twelve month high of $113.76.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.